Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,101
datasets available to search
ShareScore release 0.7.1
Dataset results
2,101 results for “Cohort studies”
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a prospectively-powered multicenter, retrospective cohort study
<p><strong>Summary </strong></p> <p>Background Both dabrafenib/trametinib (D/T) and anti-PD-1 monotherapy (PD-1) are approved adjuvant therapies for patients with stage III BRAF V600-mutant melanoma. However, there is still a lack of head-to-head comparative data. We aimed to describe efficacy and toxicity outcomes for these two standard therapies across melanoma centers.</p> <p>Methods This prospectively-powered multicenter, retrospective cohort study was conducted in 15 melanoma centers in Australia, China, Germany, Italy, Japan, UK, and US. We included adult patients with resected stage III BRAF V600-mutant melanoma who received either adjuvant D/T or PD-1. The primary endpoint was recurrence-free survival (RFS). Secondary endpoints included overall survival (OS), recurrence pattern and toxicity.</p> <p>Findings We included 598 patients with stage III BRAF V600-mutant melanoma who received either adjuvant D/T (n=393 [66%]) or PD-1 (n=205 [34%]) post definitive surgery between Jul 2015 and Oct 2022. At a median follow-up of 33 months (IQR 21-43), the median RFS was 51∙0 months (95%CI 41∙0-not reached [NR]) in the D/T group, significantly longer than 44∙8 (95%CI 28∙5-NR) in the PD-1 group (univariate: HR 0∙658, 95%CI 0∙498-0∙869, P=0∙003; multivariate: HR 0∙687, 95% CI 0∙512-0∙922, P = 0∙012), with comparable OS with PD-1 (multivariate, HR 1∙011, 95%CI 0∙637-1∙604, P>0∙95). Similar findings were observed using a restricted-mean-survival-time model. D/T survival benefits were consistent in most subgroups, except for older, male patients and those with V600K mutation. Among those who experienced recurrence, the proportion of distant metastases was higher in the D/T cohort. D/T had a higher incidence of treatment modification due to adverse events (AEs) than PD-1, but fewer persistent AEs.</p> <p>Interpretation In patients with stage III BRAF V600-mutant melanoma post definitive surgery, D/T yielded better RFS than PD-1, with higher transient but lower persistent toxicity, and comparable OS. D/T is potentially a superior adjuvant option compared with PD-1. </p>
Investigating the Impact of Internet Use in Patients with Cardiac Arrhythmias: A Cohort Study - Full Dataset SPSSv27
<p><span lang="EN-GB">The full dataset used for calculations. Statistical analysis was performed on IBM SPSS V27.</span></p>
Blood cell differential count discretization modeling predicts survival in adults reporting to the emergency room: a retrospective cohort study
<p><strong>Objectives</strong>: to assess survival predictivity of baseline blood cell differential count (BCDC), discretized according to two different methods, in adults visiting the Emergency Room (ER) for illness or trauma over one-year. </p> <p><strong>Design</strong>: Retrospective cohort study of hospital records. </p> <p><strong>Setting</strong>: Tertiary care public hospital in northern Italy. </p> <p><strong>Participants</strong>: 11052 patients aged > 18 years, consecutively admitted to the ER in one year, and for whom BCDC collection was indicated by ER medical staff at first presentation.</p> <p><strong>Primary outcome</strong>: Survival was the referral outcome for explorative model development. Automated BCDC analysis at baseline assessed hemoglobin, red cell mean volume (MCV) and distribution-width (RDW), platelet distribution-width (PDW), plateletcrit (PCT), absolute red blood cells, white blood cells, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platelets. Discretization cutoffs were defined by Benchmark and Tailored methods. Benchmark cutoffs were stated on laboratory reference values (CLSI). Tailored cutoffs for linear, sigmoid-shaped and for U-shaped distributed variables were discretized by Maximally Selected Rank Statistics and by Optimal-Equal Hazard Ratio respectively. Explanatory variables (age, gender, ER admission during SARS-CoV2 surges, in-hospital admission) were analyzed using Cox multivariable regression. ROC curves were drawn by sum of Cox-significant variables for each method.</p> <p><strong>Results</strong>: Of 11052 patients (median age 67 years, IQR 51–81, 48% female), 59% (n=6489) were discharged and 41% (n=4563) were admitted in hospital. After a 306-day median follow up (IQR 208–417 days), 9455 (86%) patients were alive and 1597 (14%) deceased. Increased HRs were associated with age >73-years (HR=4.6 CI=4.0–5.2), in-hospital admission (HR=2.2 CI=1.9–2.4), ER admission during SARS-CoV2 surges (Wave-I HR=1.7 CI=1.5–1.9); Wave-II HR=1.2 CI=1.0–1.3). Gender, hemoglobin, MCV, RDW, PDW, neutrophils, lymphocytes and eosinophils counts were significant in overall. Benchmark-BCDC model included basophils and platelet count (AUROC 0.74). Tailored-BCDC model included monocyte counts and plateletcrit (AUROC 0.79).</p> <p><strong>Conclusions</strong>: baseline discretized BCDC provides meaningful insight regarding Emergency Room patients survival.</p>
Cohort Study of Adult Patients With Down Syndrome at Risk of Developing Alzheimer's Disease (TriAL21)
ClinicalTrials.gov study NCT03901261. IPD Sharing: Not stated. Countries: 1. Publications: 15.
A Cohort Study of Non-surgical Treatment and Exercise Rehabilitation in Patients With Anterior Cruciate Ligament Rupture
ClinicalTrials.gov study NCT05403905. IPD Sharing: NO. Countries: 1. Publications: 1.
Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research: Prospective Readiness Cohort Study
ClinicalTrials.gov study NCT02114372. IPD Sharing: Not stated. Countries: 1. Publications: 2.
H1N1v Vaccination of Pregnant Women: A Longitudinal Cohort Study Characterizing Influenza A H1N1v Vaccination in Pregnant Women
ClinicalTrials.gov study NCT01012557. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer
ClinicalTrials.gov study NCT01745757. IPD Sharing: YES. Countries: 1. Publications: 3.
A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
ClinicalTrials.gov study NCT05938309. IPD Sharing: NO. Countries: 1. Publications: 10.
European Ankylosing Spondylitis Infliximab Cohort (EASIC) Follow up Registration Study
ClinicalTrials.gov study NCT01286545. IPD Sharing: Not stated. Countries: 6. Publications: 9.
Boston Birth Cohort Study
ClinicalTrials.gov study NCT03228875. IPD Sharing: NO. Countries: 1. Publications: 8.
Cohort Study to Investigate the Association Between Changes in Brain Volume and Postoperative Cognitive Dysfunction
ClinicalTrials.gov study NCT02045004. IPD Sharing: UNDECIDED. Countries: 1. Publications: 31.
Chinese Pregnant Woman Cohort Study
ClinicalTrials.gov study NCT03403543. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Mechanical Power As a Predictor for Weaning in Chronic Obstructive Pulmonary Disease Patients :Prospective Cohort Study.
ClinicalTrials.gov study NCT06493929. IPD Sharing: NO. Countries: 1. Publications: 9.
Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study
ClinicalTrials.gov study NCT05860400. IPD Sharing: Not stated. Countries: 1. Publications: 16.
A Multicenter, Prospective, Non-interventional Cohort Study to Evaluate the Safety and Treatment Pattern of Sodium Zirconium Cyclosilicate for Hyperkalaemia Management in Real World Practice in China
ClinicalTrials.gov study NCT05271266. IPD Sharing: YES. Countries: 1. Publications: 1.
COMPLEX Registry - a Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting with CompLEX and Calcified Coronary Artery Disease
ClinicalTrials.gov study NCT06075602. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Precision Medicine to Predict the Trajectory of Liver Cirrhosis: Prospective Cohort Study
ClinicalTrials.gov study NCT05899309. IPD Sharing: NO. Countries: 1. Publications: 2.
Cohort Study on Treatment of Cardiovascular Diseases With Traditional Chinese Medicine
ClinicalTrials.gov study NCT05309343. IPD Sharing: YES. Countries: 1. Publications: 1.
The COVID HOME Study: Prospective Cohort Study of Non-hospitalised COVID-19 Patients
ClinicalTrials.gov study NCT06282627. IPD Sharing: YES. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.